What is it? Why is it important?

The Annual Safety Report (ASR), also referred to in ClinO as the “periodic reporting of safety and general progress of the clinical trial”, summarises the current progress and safety information of an ongoing study.

 

An ASR report is submitted:

 

The ASR report:

  • Summarises the current recruitment/general progress status of the study
  • Contains, from all participating study sites, a list of relevant safety events, that occurred:
    • Since the last submitted ASR, or
    • Upon 1 year following study start (e.g. defined as the EC/Swissmedic approval date, whichever came last)
  • Describes the safety assessments of collected events (e.g. severity, seriousness, causal relationship to the intervention, and expectedness)
  • Describes the implemented risk-control measures needed to protect study participants

More

Because the term ASR it is not internationally used, ClinO eliminated the ASR term in its November 2024 revision. Instead, ClinO makes reference to a “periodic reporting of safety and general progress of the clinical trial”. In contrast, in ClinO-MD the ASR term remains.

 

For convenience, and because the term ASR is still widely known, used, and understood, the term remains extensively used in the Easy-GCS.

What do I need to do?

As a Site-INV, submit all safety relevant information required for the preparation of the ASR report to the SP-INV.

 

As a SP-INV submit once a year an ASR to:

  • All participating Site-INV(s)
  • EC via BASEC (e.g. use a safety form)
  • Swissmedic (for risk category B and C studies)

 

Based on study type, include in your ASR the following lists:

 

 

For international multi-centre studies with TrP/ GT / GMO:

  • Present data from study participants treated in Switzerland separately
  • For healthy volunteers, list all AEs irrespective whether they occurred in Switzerland or abroad

 

Where can I get help?

Your local Research Support Centre↧ can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

SCTO Research Tools & Resources

External Links

Swissethics – see in particular

Swissmedic – see in particular

  • Human medicine
    • Clinical trials on medicinal products
    • Safety measures in clinical trials
  • Medical devices
    • Clinical trials
    • Submissions during ongoing clinical trials

References

ICH GCP E6(R3) – see in particular guideline

  • 3.17.2 Clinical trial / Study report
  • 6.2 Factors critical to quality
  • 7.3 Management of CtoQ factors

ICH E8(R1) – see in particular

  • Glossary: definition of a CSR
  • 3.2 Critical to quality factors
  • 3.3 Approach to identify CtoQ factors
  • 5.6 Statistical analysis

ISO 14155:2026 Medical device (access liable to cost) – see in particular annexes

  • 8.4 Clinical investigation report
  • Annex D Clinical investigational report
  • Annex F Adverse event categorization

Swiss Law

ClinO – see in particular article

  • Art. 43 Reporting on the safety of participants
  • Art. 57b Reporting on the safety of participants
  • Art. 62d Applicable provisions

ClinO-MD – see in particular article

  • Art. 35 Annual reporting on the safety of participants
  • Art. 38 Notification and reporting to Swissmedic
Abbreviations
  • AE – Adverse Event
  • ASR – Annual Safety Report
  • BASEC - Business Administration System for Ethics Committees
  • ClinO – Clinical Trials Ordinance
  • ClinO-MD - Ordinance on Clinical Trials with Medical Device
  • CSR – Clinical Trial / Study report
  • DD – Device Deficiency
  • EC - Ethics Committee
  • EC/RA – Ethics Committee / Regulatory Authorities
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation - Good Clinical Practice
  • IMP – Investigational Medicinal Product
  • IMD – Investigational Medicinal Device
  • RA – Regulatory Authorities
  • SAE – Serious Adverse Event
  • SADE – Serious Adverse Device Effect
  • SADR – Serious Adverse Drug Reaction
  • SCTO – Swiss Clinical Trial Organisation
  • Site-INV – Site Investigators
  • SP-INV – Sponsor Investigator
  • SUSAR – Suspected Unexpected Serious Adverse Reaction
  • TrP / GT / GMO – Transplant Product / Gene Therapy / Genetically Modified Organisms
Conduct ↦ Safety ↦ Annual Safety Report ↦ Procedures
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Conduct ↦ Safety ↦ Annual Safety Report ↦ Procedures